Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

Table 1 Antimicrobial susceptibility of organisms from patients hospitalized with pneumonia in US medical centers (2020–2022)

Antimicrobial agent	% Susceptible per CLSI and/or FDA criteria (no. of isolates)
Antimicrobial agent	Enterobacterales (3,911)	CRE (104)	K. pneumoniae (961)	P. aeruginosa (2,130)	S. maltophilia (200)
Aztreonam-avibactam	100.0 ^a	100.0 ^a	100.0 ^a	79.1 ^a	99.5 ^a
Aztreonam	78.7	5.8	78.7	68.8
Ceftazidime-avibactam	99.6	89.4	99.6	96.1
Meropenem-vaborbactam	99.7	88.5	99.5	^c
Imipenem-relebactam	95.2 ^b	79.8 ^b	98.7	97.1
Ceftolozane-tazobactam	88.6	11.5	91.6	96.9
Piperacillin-tazobactam	79.4	6.7	78.4	77.2
Cefiderocol ^d		95.2
Ceftriaxone	74.8	5.8	77.9
Ceftazidime	79.5	11.5	78.1	81.2	22.0
Cefepime	85.5	14.4	78.9	83.3
Ertapenem	95.2	2.7	95.3
Imipenem	92.0 ^b	1.9 ^b	95.6	76.5 ^b
Meropenem	97.3	6.7	95.2	77.2
Ciprofloxacin	81.7	30.5	77.4	79.3
Levofloxacin	84.3	35.6	81.6	70.6	83.5
Gentamicin	91.0	60.6	88.6
Amikacin	95.1	73.1	96.1
Tobramycin				89.4
Tigecycline	96.2	95.2	97.0	--	91.5 ^e
TMP-SMX					97.5
Minocycline					93.5

^a % inhibited at ≤ 8 mg/L
^b All Enterobacterales species were included in the analysis, but CLSI excludes Morganella, Proteus, and Providencia species
^c Meropenem-vaborbactam is not approved to treat P. aeruginosa infections in the US
^d Cefiderocol was only tested against CRE isolates
^e At ≤ 2 mg/L
Abbreviations CLSI, Clinical and Laboratory Standards Institute; FDA, Food and Drug Administration; CRE, carbapenem-resistant Enterobacterales; TMP-SMX, trimethoprim-sulfamethoxazole

ISSN: 1471-2466